Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival

Lancet

Volumn 347, Issue 9008, 1996, Pages 1066-1071

  Gelber, Richard D ^a,l   Cole, Bernard F ^b   Goldhirsch, Aron ^c   Rose, Carsten ^d   Fisher, Bernard ^e   Osborne, C Kent ^f   Boccardo, Francesco ^g   Gray, Richard ^h   Gordon, Nahida H ⁱ   Bengtsson, Nils Olof ^j   Sevelda, Paul ^k  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Ospedale Civico Lugano   (Switzerland)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g UNIVERSITY OF GENOA   (Italy)

^h CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j Regionsjukhuset ^*  (Sweden)

^k UNIVERSITY OF VIENNA   (Austria)

^l DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME;

EID: 15844425226     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90277-9     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 relapses and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15; 71-85.
2. Boccardo F, Rubagotti A, Bruzzi P, et al, for the Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J Clin Oncol 1990; 8: 1310-20.
3. Kaufmann M, Jonat W, Caffier H, et al, for the Gynecological Adjuvant Breast Group (GABG). Adjuvant systemic risk adapted cytotoxic±tamoxifen therapy in women with node positive breast cancer. In: Salmon SE, ed. Adjuvant therapy of cancer V. Orlando: Grune and Stratton, 1987: 337-46.
4. Goldhirsh A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
5. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76.
6. Gelber RD, Cole BF, Gelber S, Goldhirsh A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat 1995; 49: 161-69.
7. Cole BF, Gelber RD, Goldhirsch A. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med 1995; 14: 1771-84.
8. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114: 621-28.
9. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am 1995; 1: 114-21.
10. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983; 1: 2-10.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
12. Weisberg S. Applied linear regression. New York: John Wiley and Sons; 1985.
13. Ludwig Breast Cancer Study Group. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984; i: 1256-60.
14. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al, for the International Breast Cancer Study Group. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994 5: 717-24.
15. Larsson L-G. Trials with adjuvant hormonal and cytotoxic treatment in operable breast cancer patients (Breast Cancer Group in Northern Sweden). EORTC - Breast Cancer Cooperative Group, June 30-July 3, 1987, abstracts books, p C2D.7.
16. Pearson OH, Hubay CA, Gordon NH, et al. Endocrine versus endocrine plus 5-drug chemotherapy in postmenopausal women with stage II, estrogen receptor positive disease. Cancer 1989; 64: 1819-23.
17. Sevelda P, Zielinski CC, Salzer H, et al. Combined adjuvant treatment with CMF-chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer: a prospective randomized study. In: Senn HJ, ed. Adjuvant therapy of primary breast cancer, St Gallen 1988: 64: (abstr).
18. Rivkin SE, Green S, Metch V, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1994; 12: 2078-85.
19. Senanayake F. Adjuvant hormonal chemotherapy in early breast cancer: early results from a controlled trial. Lancet 1984; ii: 1148.
20. Overgaard M, Christensen JJ, Johansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990; 19: 1121-24.
21. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
22. Weinstein MC, Fineberg H. Clinical decision analysis. Philadelphia: WB Saunders Company, 1980.
23. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593-603.
24. Simes RJ, Cocker K, Glasziou P, et al. Costs and benefits of adjuvant (adj) chemotherapy for breast cancer: an assessment of patient preferences. Proc ASCO 1989; 8: 52 (abstr 201).
25. Coates AS, Simes RJ. Patient assessment of adjuvant treatment in operable breast cancer. In: Williams CJ, ed. Introducing new treatments for cancer: practical, ethical and legal problems. New York: John Wiley and Sons; 1992.
26. Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes RJ, for the International Breast Cancer Study Group. Quality of life in clinical trials of adjuvant therapies. Natl Cancer Inst Monogr 1992; 11: 127-35.
27. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-59.
28. Goldhirsch A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer. N Engl J Med 1994; 330: 1308-09.
29. Schumacher M, Bastert G, Bojar H, et al, for the German Breast Cancer Study Group. Randomized 2X2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Cin Oncol 1994; 12: 2086-93.
30. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen: five-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986; 4: 459-71.
31. Osborne CK. Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In: Jordan VC, ed. Long term tamoxifen for breast cancer. Madison: University of Wisconsin Press, 1994: 181-98.